Cambridge, UK; November 12, 2018. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing gastrointestinal therapeutics, today announced that John Temperato, U.S. President and COO, will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:45am ET in New York.

To arrange a meeting or discuss Atlantic Healthcare, please email: john.temperato@atlantichc.com

Atlantic Healthcare’s most advanced development program – Camligo™ (alicaforsen enema) is undergoing a pivotal Phase 3 trial for orphan designated pouchitis, due to report in H1 2019. Pouchitis is a rare and serious form of Inflammatory Bowel Disease (IBD), which we estimate impacts the lives of approximately 200,000 patients in the U.S. and Europe. There is no approved treatment for pouchitis, hence there remains a significant unmet clinical need.

About Atlantic Healthcare plc (www.atlantichc.com)

“Atlantic Healthcare” is a specialist pharmaceutical company focused on developing and commercializing gastrointestinal therapeutics, which address unmet patient needs and rare diseases. The Company owns the exclusive worldwide rights to alicaforsen, a promising new drug for the treatment of inflammation. Its most advanced development program – Camligo™ (alicaforsen enema) – is undergoing a pivotal Phase 3 trial for pouchitis. In addition, work is ongoing to develop and deepen the pipeline for alicaforsen with treatments for Crohn’s disease, ulcerative colitis and other gastrointestinal (GI) indications.

Atlantic Healthcare is led by an experienced international Board and Leadership Team, with deep roots and a proven track record in the pharmaceutical industry.

About Alicaforsen

Alicaforsen is a novel antisense drug. It is a pipeline in a drug, with the potential to establish a new class of therapy for the treatment of multiple inflammatory gastrointestinal disorders. For more information about alicaforsen and how it works, please go to: www.atlantichc.com/alicaforsen

About Camligo™ (alicaforsen enema)

Camligo™ (alicaforsen enema) formulation is currently in a pivotal Phase 3 trial agreed with U.S., Canadian and European regulatory agencies in patients with active pouchitis. The trial has completed enrollment of 138 patients to approximately 40 trial centers across the U.S., Canada, Europe, and Israel, and is expected to report preliminary data in H1 2019.

Trials have shown Camligo™ to be a safe, well tolerated and effective treatment, which delivers a durable response for pouchitis patients.

For published papers please go to: www.atlantichc.com/published-papers

Forward Looking Statements

While Atlantic Healthcare believes the forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties, including, among others, that the development of alicaforsen for the stated uses may not proceed due to safety, efficacy or other reasons. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in this press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.

For more information please contact:

Atlantic Healthcare
Adam Michael (Head of Communications)

+44 1799 512 055
+44 777 588 1813

adam.michael@atlantichc.com

U.S. Investor Relations and Media
Lazar Partners
Fern Lazar / David Carey

+1 212-867-1762

atlantic.healthcare@lazarpartners.com